Full length articleSearching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
Introduction
Down syndrome is the most common chromosomal abnormality leading to intellectual disabilities (Gardiner et al., 2010). The excess gene dosage in Down syndrome is associated with characteristic facial and physical features, deficits in immune and endocrine systems, congenital heart defects and delayed growth (Roizen and Patterson, 2003) combined with deficits in learning and language that lead to a mild-to-moderate global cognitive impairment (Lott and Dierssen, 2010, Zigman et al., 2008). Given the advances in medical and social care of the past decades, the life expectancy of individuals with Down syndrome has greatly increased, such that many live well into their 60s and 70s. This means that pathological conditions associated for aging, as is the case for dementia, are also more present in this population.
Alzheimer's disease is the most common form of dementia that develops in individuals with Down syndrome, as in the general population (Zigman et al., 1996). Unfortunately, no disease-modifying drugs are yet available to treat dementia in Down syndrome. In that sense, biomarker discovery and the development of sensitive cognitive screening tools will be essential for earlier diagnosis and better therapeutic management.
In the present review we will describe the pathophysiology of Alzheimer's disease in Down syndrome examining the best validated pharmacological targets that are presently considered for clinical trials. In particular we examine the dysfunction of different genes and neurotransmitter-based systems, including the cholinergic deficit concomitant with the metabolic deregulation of the NGF metabolic pathway, a novel neurochemical pathway that has been validated as a potential pharmacological target for the treatment of Alzheimer's disease pathology in Down syndrome. We further examine the relevance of biological markers for an early diagnosis of Alzheimer's disease in Down syndrome and the recent clinical trials designed to assess the possible disease-modifying activity of new drugs under investigation.
Section snippets
Alzheimer's disease in Down syndrome: from clinical phenotypes to neurobiology
The amyloid cascade hypothesis posits that overproduction or impaired clearance of amyloid-β (Aβ) causes Alzheimer's disease as a result of the aggregation of monomeric Aβ species into higher-molecular-weight oligomers that result in neuronal loss (Selkoe and Hardy, 2016). Individuals with Down syndrome show an increased risk of developing Alzheimer's disease, as a consequence of trisomy 21 with the associated over-production of the amyloid precursor protein (APP) and of its amyloidogenic
Diagnosing Alzheimer's disease in Down syndrome: the role of biological markers
Although there are specific cognitive screening tests designed for individuals with Down syndrome, there are no formal guidelines for the diagnosis of dementia in this population, unlike in the elderly or in familial genetic cases (e.g. ICD-10 criteria). Further challenges to the diagnosis of dementia in Down syndrome are the atypical presentation of Alzheimer's symptoms (e.g. beginning mainly with changes in mood and behaviour rather than with memory problems), the difficulty in dissecting
Correcting the dysfunction of neurotransmitter systems
Different neurotransmitter-based systems are known to play a central role in cognitive decline in Down syndrome (Das et al., 2014). Neurodegeneration of basal forebrain cholinergic neurons (BFCNs) is a primary event in the pathogenesis of Alzheimer's disease in Down syndrome (Salehi et al., 2006), but recent studies on cognitive dysfunction emphasize the relevance of other neurotransmitter-based systems such as an imbalance between excitatory (i.e. glutamatergic) and the major inhibitory system
Overview and challenges for testing disease-modifying drugs in Down syndrome
Recent efforts have been directed to develop disease-modifying drugs to counteract the progression of Alzheimer's disease in Down syndrome (Hartley et al., 2015). The design of clinical trials in this population raises methodological challenges in studying cognitive functioning and assessing the neuroprotective effect of a potential disease-modifying drug. According to the European Medical Association and the Food and Drug Administration, a drug is considered to be disease modifying when it is
Conclusions and perspectives
Preclinical studies point at several strategies and novel targets to improve or protect cognitive function in Down syndrome. These include correcting neurotransmitter deficits, such as cholinergic, noradrenergic and serotonergic neurodegeneration, reducing GABA hyperactivity, targeting glutamate excitotoxicity as well as inhibiting DYRK1A activity and correcting NGF metabolic deregulation. The field of biomarker discovery in Down syndrome is another fertile territory of active investigation,
Acknowledgements
FC would like to acknowledge support from the Neuropsychopharmacology Research Program 2017 (RC-06-01) and from the Institute for Research on Mental Retardation and Brain Aging, Troina, Italy. MFI was the recipient of the Herbert H. Jasper Postdoctoral Research Fellowship in Neurosciences from the Groupe de Recherche sur le Système Nerveux Central (GRSNC), Université de Montréal (2016–2017), and was also supported by a Bourse de Recherche Postdoctorale from the Fonds de recherche du Québec -
References (215)
- et al.
DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications
Pharmacol. Ther.
(2015) - et al.
Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice
Neurobiol. Dis.
(2014) - et al.
Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs
Exp. Neurol.
(2000) - et al.
Developmental pattern of muscarinic receptors in normal and Down's syndrome fetal brain--an autoradiographic study
Neurosci. Lett.
(1991) - et al.
Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome
Neurobiol. Dis.
(2014) - et al.
The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes
Brain Res Brain Res Rev.
(2003) - et al.
Neuronal maturation in the foetal brain in Down's syndrome
Early Hum. Dev.
(1989) - et al.
Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome
Neurobiol. Learn Mem.
(2008) - et al.
Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin
Cell
(1997) - et al.
GABAB-GIRK2-mediated signaling in Down syndrome
Adv. Pharmacol.
(2010)
Effects of trophic factors on the CNS cholinergic phenotype
Progress. brain Res.
Formoterol, a long-acting beta2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome
Biol. Psychiatry
Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome
Progress. neuro-Psychopharmacol. Biol. Psychiatry
Selective loss of central cholinergic neurons in Alzheimer's disease
Lancet
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial
Lancet Neurol.
Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future
Progress. brain Res.
Behavioural and psychological symptoms of dementia in Down syndrome: early indicators of clinical Alzheimer's disease?
Cortex; a J. devoted the Study Nerv. Syst. Behav.
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome
Neurosci. Lett.
The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease
Mol. Cell. Neurosci.
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer
Neurobiol. Dis.
Noradrenergic regulation of inflammatory gene expression in brain
Neurochem. Int.
Acidic FGF induces NGF and its mRNA in the injured neocortex of adult animals
Mol. brain Res.
Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice
Neurobiol. Dis.
Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits
Biochim. Et. Biophys. Acta (BBA)-Mol. Basis Dis.
Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease
Mol. Brain Res.
Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome
Exp. Neurol.
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Alzheimer'S. Dement.: J. Alzheimer'S. Assoc.
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B
Alzheimer'S. Dement.: J. Alzheimer'S. Assoc.
Down syndrome and Alzheimer's disease: common pathways, common goals
Alzheimer'S. Dement.: J. Alzheimer'S. Assoc.
Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons Implications for the regulation of motor learning and neuronal survival
J. Biol. Chem.
Behavioral comparison of 4 and 6 month-old Ts65Dn mice: age-related impairments in working and reference memory
Behav. brain Res.
Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen
Neurobiol. Aging
Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function
Behav. brain Res.
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease
Neurochem. Int.
Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome
Trends Pharmacol. Sci.
Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype
J. Neurosci.
The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease
J. Alzheimer's dis.
Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities
Br. J. Clin. Psychol.
Is it possible to improve neurodevelopmental abnormalities in Down syndrome?
Rev. Neurosci.
Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study
Arch. General. Psychiatry
DYRK1A: a potential drug target for multiple Down syndrome neuropathologies
CNS Neurol. Disord. Drug Targets
The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand
J. Cereb. Blood Flow. Metab.
Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory
J. Cell Sci.
Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome
J. Neurosci.: Off. J. Soc. Neurosci.
Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial
Transl. Psychiatry
Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies
Brain: a J. Neurol.
Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade
Proc. Natl. Acad. Sci.
Amyloid β-induced nerve growth factor dysmetabolism in Alzheimer disease
J. Neuropathol. Exp. Neurol.
The Anti-Inflammatory Role of Minocycline in Alzheimer´ s Disease
Curr. Alzheimer Res.
Depression and the onset of dementia in adults with mental retardation
Am. J. Ment. Retard.: AJMR
Cited by (12)
Untangle the mystery behind DS-associated AD – Is APP the main protagonist?
2023, Ageing Research ReviewsPolyphenols and neuroprotection: Therapeutic implications for cognitive decline
2022, Pharmacology and TherapeuticsCitation Excerpt :The dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) gene is located within the Down syndrome critical region on chromosome 21 and has a central role in the pathophysiology of early onset AD by different molecular mechanisms and signalling pathways that lead to tau hyperphosphorylation and amyloid pathologies (Becker, Soppa, & Tejedor, 2014). On the basis of this evidence, the inhibition of DYRK1A activity has been explored as a new therapeutic approach to treat early onset Alzheimer-type pathology and cognitive decline in Down syndrome (Caraci et al., 2017; Martínez Cué & Dierssen, 2020). EGCG is a potent and selective inhibitor of DYRK1A activity (Bain, McLauchlan, Elliott, & Cohen, 2003) and it rescues the cognitive deficits of both segmental trisomy 16 (Ts65Dn) and transgenic mice overexpressing DYRK1A as well as memory recognition and working memory deficits in DS individuals (De la Torre et al., 2014; de la Torre et al., 2016).
Preventive effect of nasal Timosaponin BII-loaded temperature-/ion-sensitive in situ hydrogels on Alzheimer's disease
2021, Journal of Traditional Chinese Medical SciencesCitation Excerpt :Alzheimer’s disease (AD) was first discovered by German doctors in the early 19th century. Due to its irreversibility, the disease is lethal in the elderly population after the occurrence of its core lethal factors, such as cancer, cardiovascular and cerebrovascular disease, and malignant tumors.1–3 In 2013, official death certificates recorded 84,767 deaths from AD, making it the sixth leading cause of death in the United States and the fifth leading cause of death in Americans aged 65 and over.
Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome
2018, NeuroImage: ClinicalCitation Excerpt :Finally, future DTI studies may help clarify the impact of amyloid and tau accumulation on the white matter of the DS brain, for example in the striatum. In general, high powered studies that take a prospective longitudinal approach will be critical in increasing our understanding of these mechanisms and identifying biomarkers for tracking dementia development in DS (Caraci et al., 2017). This research will ultimately have great significance for the quality of life of the increasing number of individuals with DS living into their 50′s and beyond, and well as for AD prevention in the general population.
Low TGF-β1 plasma levels are associated with cognitive decline in Down syndrome
2024, Frontiers in PharmacologyBiological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model
2023, Current Neuropharmacology